<i>STAT3</i> Polymorphism Predicts Interferon-Alfa Response in Patients With Metastatic Renal Cell Carcinoma

Abstract

The present study suggested that the STAT3 polymorphism is a useful diagnostic marker to predict the response to IFN-alpha therapy in patients with MRCC. An efficient response marker for IFN-alpha needs to be utilized to establish individual optimal treatment strategies, even when newer drug therapies are used as first line treatments for MRCC.